Mayo Clinic Biotrust collaborator, Dr. Alan Marmorstein, PhD (Mayo Clinic), along with Drs. Kapil Bharti, PhD (NIH/National Eye Institute), Sheldon Miller, PhD (NIH/National Eye Institute), and Jeffrey Stern, MD, PhD (Neural Stem Cell Institute), discussed current efforts of applying stem cells toward the treatment of retinal disease. Focusing on age-related macular degeneration (AMD), a condition defined by a gradual loss of central vision, the speakers discussed using iPS-derived retinal pigment epithelium (RPE) to slow the progression of AMD. By using an RPE patch to replace those RPE cells destroyed by degeneration, photoreceptors in the eye are maintained, thereby preventing the gradual vision loss seen in individuals affected by AMD. Future research is needed to determine the most efficient and effective balance between various phases of iPS derived RPE differentiation, but the trials thus far are promising and give hope to those affected by the disease.